Shijie Medical Announces Tens of Millions Series A+ Financing, Accelerating Growth in Transradial Neurointervention

VCBeat has learned that,Recently, Shijie Medical Technology (Guangzhou) Co., Ltd. (“Shijie Medical”) announced the completion of its tens-of-millions RMB Series A+ financing round. This marks additional investment from Wuming Investment, a renowned angel investment firm, following Shijie Medical’s successful Series A financing led by Shandong Hexin in February 2023.

This round of financing will strongly support Shijie Medical’s R&D innovation and market expansion in the field of transradial-access neurointerventional devices, accelerating the commercialization of its core product pipeline.

Since its establishment in 2021, Shijie Medical has been committed to pioneering a novel pathway for the transradial treatment of stroke. With its product portfolio strategically centered on transradial neurointervention, the company has provided innovative transradial neurointerventional solutions for patients, physicians, the national healthcare insurance system, and hospitals, yielding significant socioeconomic benefits.

Furthermore, Shijie Medical has established a comprehensive R&D system for neurointerventional medical devices, encompassing laboratories and advanced equipment that cover the entire chain from research and development to production and quality testing, ensuring that every stage meets international leading standards.

VCBeat has learned thatCurrently, Shijie Medical has five products approved by the NMPA for market launch: introducer sheaths, neurovascular guiding catheters, transradial distal access neurovascular guiding catheters, neurovascular angiographic catheters, and neurovascular delivery support catheters. The company has completed its commercialization layout through tendering and online listing across all provinces in China. In addition, Shijie Medical has multiple other products that have completed research and development and entered the clinical registration phase. This further demonstrates Shijie Medical’s strong capabilities in technological innovation and market application.

As a key investor in Shijie Medical, Shenzhen Wuming Investment Management Co., Ltd.’s additional investment not only demonstrates its firm confidence in Shijie Medical’s future growth potential but also acknowledges the professional expertise and innovative spirit of Shijie Medical’s team in the field of neurointerventional devices. Wuming Investment will continue to support Shijie Medical’s comprehensive development in product R&D, clinical trials, and market promotion, helping it realize its vision of becoming a global leader in transradial neurointerventional devices.

Mr. Cai Shizhou, Founder and CEO of Shijie Medicalstated: “We sincerely appreciate Wuming Investment’s continued support for Shijie Medical! This Series A+ financing round will provide the company with additional resources and momentum to accelerate our product market deployment, medical education initiatives, new product R&D, and overseas regulatory registrations. We remain committed to delivering safer and more effective neurointerventional treatment solutions for patients worldwide, while making greater contributions to the development of the healthcare industry.”

Mr. Wu Jianlin, Partner at Shandong Hexinstated: “We are greatly encouraged by Shijie Medical’s achievements in the field of neurointerventional devices and remain confident in the company’s future. Shijie Medical has not only taken a leading position in technological innovation within the industry but also demonstrated strong execution capabilities and forward-thinking vision in market application and commercialization. We believe that, through this Series A+ financing round, Shijie Medical will further consolidate its leadership position in the global neurointerventional market and provide more high-quality treatment options for patients worldwide.”

Mr. Zhang Zongyou, Partner at Wuming Investmentstated: “We are delighted to continue supporting the development of Shijie Medical. Since its establishment, the company has demonstrated strong innovation capabilities and market potential in the field of neurointerventional devices. The team at Shijie Medical has not only achieved significant results in technological research and development but also exhibited exceptional execution in clinical application and commercialization. We believe that with this Series A+ financing round, Shijie Medical will be able to further expand its influence in the global neurointerventional market and bring more innovative treatment solutions to patients.”

Mr. Zhang Zongyou further stated, “Wuming Investment has been committed to supporting forward-looking and innovative healthcare enterprises. Shijie Medical’s focus and achievements in the field of transradial approach neurointerventional devices align perfectly with our investment philosophy. We look forward to continuing our collaboration with Shijie Medical to jointly advance medical technology and make greater contributions to global healthcare.”

As a partner at Wuming Investment, Mr. Zhang Zongyou brings extensive experience and unique insights to the healthcare investment sector. His endorsement not only reflects Wuming Investment’s recognition of Shijie Medical but also signals Shijie Medical’s capacity to navigate the myriad opportunities and challenges that lie ahead on its development path.

Shijie Medical Technology (Guangzhou) Co., Ltd. was established in October 2021 as a high-tech enterprise specializing in the research and development, manufacturing, and sales of vascular interventional devices. Committed to becoming a global leader in transradial neurointerventional devices, the company adheres to its core values of “Innovation, Quality, Integrity, and Win-Win Cooperation.” It has innovatively developed a range of transradial neurointerventional products to meet clinical needs, ensuring safer and more effective treatments for patients.

Wuming Investment is a renowned investment firm specializing in the healthcare and medical sector, boasting extensive industry resources and investment expertise. Dedicated to identifying and supporting innovative healthcare enterprises with high growth potential, Wuming Investment facilitates their rapid expansion and value enhancement through the infusion of capital and strategic resources.